Efpe
Asset
Activates GLP-1 receptors to increase glucose-dependent insulin secretion, suppress appetite, and promote weight loss.
- Stage
- Approved
- Modality
- Peptide
- Target
- GLP1R
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Obesity
Approved, hitnews.co.kr, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.